John Parkinson

The FDA says the recall being performed by Wilcox Ice Cream is doing this out of concern for listeria contamination in the products.

A study demonstrates the microbiome changes and how restoration of the gut flora is warranted when patients are dealing with recurrent bouts of the health care-associated infection.

Acurx Pharmaceuticals reported topline data from a small phase 2 study on their antibiotic, ibezapolstat, which showed it had a 96% cure rate.

Shionogi’s therapy, ensitrelvir, was found to reduce and prevent these issues.

This week we covered antibiotic de-escalation, the approved fecal microbiota options for prevention of recurrent Clostridioides difficile, the CDC's recommendations for HCV testing in the pediatric populations, and examining pragmatic approaches to skin and soft tissue Infections.

At the American Association for the Study of Liver Diseases (AASLD) meeting held last week, Barinthus Biotherapeutics announced the presentation of data from its hepatitis B clinical trials.

Seres Therapeutics reported its financials recently including the performance of it therapy, Vowst, as well as updates on its business and one of its investigational therapies.

The investigational agent, afabicin, was developed by private company, Debiopharm, and a clinician offers some insights on the therapy in these 2 therapeutic areas.

With the FDA approval of 2 of these products, which are indicated for recurrent Clostridioides difficile infection (CDI), a study reviewed which types of clinicians are prescribing them and the protocols in using them.

Although the current reimbursement model makes it difficult for pharmaceutical companies to recoup their investments, a subscription model like the prospective congressional bill, the Pasteur Act, may help change that paradigm. In addition, there are international measures being carried out that may bring about changes.

The companies announced a licensing agreement on cefepime-taniborbactam.

The Leapfrog Group finds there were improved health care-associated infection (HAIs) rates following an earlier spike during the acute phase of the COVID-19 pandemic.

With these infections being problematic, a newer antiviral offers an alternative option for these patients.

The Centers for Disease Control and Prevention (CDC) looked at outbreak-related deaths and found a majority of decedents had existing preexisting conditions.

This week's stories include study data on 2 RSV vaccines for seniors; an update on C diff therapies; looking at Ending the HIV Epidemic initiative; and a study on Paxlovid and Long COVID.

The patient advocacy organization has events in place and is ready to launch its annual C diff awareness campaign.

In this week's news, CDC sent out a health advisory to change the prescribing recommendations for the newer preventative respiratory syncytial virus (RSV) monoclonal antibody; a clinician discusses the ongoing challenges presented with critically ill patients and the timing and scope of antibiotic prescribing practices; and antidepressants were associated with a greater risk of Clostridioides difficile infection (CDI).

A new study that went beyond the current standard of testing for the respiratory virus resulted in greater incidence rates and a truer accounting of case loads.

The company dosed its first study participant with its investigational vaccine, mRNA-1083. And this follows recent data reported from their phase 1/2 trial where the vaccine showed strong immunogenicity against influenza and COVID-19, with an acceptable reactogenicity and safety profile.

The federal agency sent out a health advisory to change the prescribing recommendations for the newer preventative respiratory syncytial virus (RSV) monoclonal antibody.

A joint meeting of WHO and FAO offered this assessment of these viruses that millions of people encounter.

If approved, it would become the first nasal flu vaccine to be self-administered.

A clinician discusses the ongoing challenges presented with critically ill patients and the timing and scope of antibiotic prescribing practices.

This week's news included a new study that showed the association with Epstein-Barr virus reactivation and sets the need for an antiviral clinical trial with cardiopulmonary exercise testing as an endpoint; a clinician weighs in on the limited use of novel, gram-negative antibiotics; and the discussion around increasing hepatitis C testing for the pediatric population.

The antiretroviral, lenacapavir (Sunlenca 463.5 mg/1.5 mL injection), had reported resistance in only a minority of study participants according to the latest findings released at a conference.

The Pfizer product is indicated to prevent the 5 most common serogroups causing meningococcal disease in adolescents and young adults.

A study looked at patients’ microbiome profiles to see if they differed at study entry and whether microbiome recovery was dissimilar between subgroups, post-treatment.

A study reported at IDWeek looked at this population and found gaps in testing.

Company plans to start recruiting for its REPREVE study this year.

A study showed the Clostridioides difficile treatment remained effective after subsequent systemic antibiotic exposure.